Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Aug 3;13(15):4540.
doi: 10.3390/jcm13154540.

Enthesitis in IBD Patients

Ivna Akrapovic Olic  1   2 , Jonatan Vukovic  1   2 , Mislav Radic  1   3 , Zeljko Sundov  1   2
Affiliations
Review

Enthesitis in IBD Patients

Ivna Akrapovic Olic et al. J Clin Med. .

Abstract

Inflammatory bowel disease (IBD) is marked by chronic inflammation of the gastrointestinal tract and encompasses two major subtypes, Crohn's disease (CD) and ulcerative colitis (UC). IBD is frequently accompanied by extraintestinal manifestations (EIMs), with axial and peripheral spondyloarthritis (SpA) being the most common. Enthesitis, an inflammation of the bone insertions of capsules, ligaments, and tendons, represents an initial lesion in SpA. However, enthesitis remains an underestimated and often obscured EIM. The early detection of subclinical entheseal involvement in IBD patients using ultrasound (US) could provide an opportunity for timely intervention. US is a more feasible and affordable approach than magnetic resonance imaging (MRI). While previous meta-analyses have reported on the incidence and prevalence of SpA in IBD, specific attention to enthesitis has been lacking. Therefore, this narrative review aims to assess the current knowledge on existing IBD-SpA cohorts, focusing specifically on enthesitis.

Keywords: Crohn’s disease; enthesitis; extraintestinal manifestations; inflammatory bowel disease; ulcerative colitis.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

Figure 1
Figure 1
Study selection.
See this image and copyright information in PMC

References

    1. Adolph T.E., Meyer M., Schwärzler J., Mayr L., Grabherr F., Tilg H. The metabolic nature of inflammatory bowel diseases. Nat. Rev. Gastroenterol. Hepatol. 2022;19:753–767. doi: 10.1038/s41575-022-00658-y. - DOI - PubMed
    1. Torres J., Mehandru S., Colombel J.F., Peyrin-Biroulet L. Crohn’s disease. Lancet. 2017;389:1741–1755. doi: 10.1016/S0140-6736(16)31711-1. - DOI - PubMed
    1. Ungaro R., Mehandru S., Allen P.B., Peyrin-Biroulet L., Colombel J.F. Ulcerative colitis. Lancet. 2017;389:1756–1770. doi: 10.1016/S0140-6736(16)32126-2. - DOI - PMC - PubMed
    1. Harbord M., Annese V., Vavricka S.R., Allez M., Acosta M.B.-D., Borberg K., Burisch J., De Vos M., De Vries A.-M., Dick A.D., et al. The First European Evidence-based Consensus on Extra-intestinal Manifestations in Inflammatory Bowel Disease. [(accessed on 27 November 2015)];J. Crohn’s Colitis. 2015 10:239–254. doi: 10.1093/ecco-jcc/jjv213. Available online: http://www.spgp.pt/media/1069/pdf8.pdf. - DOI - PMC - PubMed
    1. Vavricka S.R., Schoepfer A., Scharl M., Lakatos P.L., Navarini A., Rogler G. Extraintestinal Manifestations of Inflammatory Bowel Disease. [(accessed on 2 July 2015)];Inflamm. Bowel Dis. 2015 21:1982–1992. doi: 10.1097/MIB.0000000000000392. Available online: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4511685. - DOI - PMC - PubMed

LinkOut - more resources